Cipla dividend 2024: Mumbai-based drugmaker Cipla has announced a final dividend of Rs 13 or 650 per cent per equity share of the face of Rs 2 for the financial year that ended March 31, 2024.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

"Recommended payment of a final dividend of Rs. 13 per equity share (face value of Rs. 2 per equity share) for the financial year ended 31st March 2024," the company said in an exchange filing.

Cipla dividend 2024 - Record Date

The drugmaker has also fixed August 2, 2024 as the record date to identify the eligibility of investors. A record date is important for companies to identify the eligibility of shareholders for a corporate announcement.

Cipla dividend 2024 - Payment Date

According to the company, the dividend amount will be paid to eligible investors within 30 days from the date of the Annual General Meeting.

"The dividend, upon approval by the shareholders, will be paid within 30 days from the date of the Annual General Meeting. The record date for the purpose of payment of final dividend, if declared, shall be 2nd August 2024," the filing reads.

Meanwhile, Cipla on Wednesday said it has received one inspectional observation in Form 483 from the US health regulator for its manufacturing facility at Kurkumbh in Maharashtra.

As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

A routine current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the company's manufacturing facility at Kurkumbh, Maharashtra from April 29, 2024, to May 8, 2024, Cipla said in a regulatory filing.

"On conclusion of the inspection, the company has received one inspectional observation in Form 483," it added.

The company will work closely with the USFDA and is committed to addressing this observation comprehensively within the stipulated time, Cipla said.